AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17587452 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended-learning approach (study arm A)
Number of subjects: 0
Study 17587452 — intervention group
Group type: COMPARATOR
Intervention: Classical approach (study arm B)
Number of subjects: 0
Study 16027402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium 100 mg every 8 hours for 7 days
Number of subjects: 0
Study 16027402 — intervention group
Group type: COMPARATOR
Intervention: Warfarin + placebo
Number of subjects: 0
Study 12412994 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA plus suplatast tosilate (300 mg/day tid)
Number of subjects: 38
Study 12412994 — intervention group
Group type: COMPARATOR
Intervention: UDCA alone (600 mg/day tid)
Number of subjects: 38
Study 10348784 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral moxifloxacin (400 mg)
Number of subjects: 8
Study 10348784 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous moxifloxacin (400 mg)
Number of subjects: 8
Study 8749228 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg 3 times daily
Number of subjects: 30
Study 8749228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1673844 — intervention group
Group type: EXPERIMENTAL
Intervention: d-propranolol
Number of subjects: 11
Study 1673844 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 1673844 — intervention group
Group type: EXPERIMENTAL
Intervention: racemic propranolol
Number of subjects: 11
Study 7030977 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 39
Study 7030977 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 39
Study 31064406 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tube fastener
Number of subjects: 500
Study 31064406 — intervention group
Group type: COMPARATOR
Intervention: Adhesive tape
Number of subjects: 500
Study 27683282 — intervention group
Group type: EXPERIMENTAL
Intervention: 600,000 IU vitamin-D
Number of subjects: 60
Study 27683282 — intervention group
Group type: COMPARATOR
Intervention: 300,000 IU vitamin-D
Number of subjects: 60
Study 27683282 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 25526678 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 0
Study 25526678 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH)
Number of subjects: 0
Study 23669513 — intervention group
Group type: EXPERIMENTAL
Intervention: Early limited formula (10 mL formula by syringe after each breastfeeding, discontinued when mature milk production began)
Number of subjects: 40
Study 23669513 — intervention group
Group type: COMPARATOR
Intervention: Control (continued exclusive breastfeeding)
Number of subjects: 40
Study 23669513 — intervention group
Group type: EXPERIMENTAL
Intervention: Early limited formula
Number of subjects: 40
Study 23669513 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 20972878 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity resistance training (LSR) at 50% of one repetition maximum for 10 weeks, performed twice a week with five sets of ten repetitions and 30 seconds inter-set rest period
Number of subjects: 26
Study 20972878 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study 18984831 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early mobilization and task-oriented physical therapy
Number of subjects: 12
Study 17875820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient air pollution exposure (measured levels of nitrogen, sulfur and carbon oxides, and particulate matter)
Number of subjects: 40
Study 15497601 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridian exercise
Number of subjects: 0
Study 12620953 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (2 micro g x kg(‐1) x min(‐1))
Number of subjects: 60
Study 12620953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12620953 — intervention group
Group type: COMPARATOR
Intervention: Dopamine (2.5 micro g x kg(‐1) x min(‐1))
Number of subjects: 60
Study 10197489 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 30
Study 10197489 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 30
Study 7473239 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan (3 g l-1)
Number of subjects: 10
Study 7473239 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of BCAA (6 g l-1)
Number of subjects: 10
Study 7473239 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of BCAA (18 g l-1)
Number of subjects: 10
Study 7473239 — intervention group
Group type: COMPARATOR
Intervention: Control (6% sucrose)
Number of subjects: 10
Study 2249160 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 14
Study 2249160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7383488 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mother-infant contact program during the first 12 hours after cesarean section
Number of subjects: 40
Study 7383488 — intervention group
Group type: COMPARATOR
Intervention: Traditional procedures allowing only brief contact during the first 12 hours
Number of subjects: 40
Study 29999208 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied to the tibia bone for 100 seconds prior to PPCI and at 24 and 72 hours post-PPCI.
Number of subjects: 24
Study 29999208 — intervention group
Group type: COMPARATOR
Intervention: Non-laser therapy (NLT) with power source turned off.
Number of subjects: 24
Study 26330561 — intervention group
Group type: EXPERIMENTAL
Intervention: Early home-based group education on renal replacement therapy (RRT) options
Number of subjects: 80
Study 26330561 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 80
Study 26330561 — intervention group
Group type: EXPERIMENTAL
Intervention: Early home-based group education on RRT options
Number of subjects: 80
Study 24571755 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated EV71 vaccine
Number of subjects: 12000
Study 24571755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12000
Study 22464760 — intervention group
Group type: EXPERIMENTAL
Intervention: 17β‐estradiol (4 mg/d)
Number of subjects: 472
Study 22464760 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 472
Study 19618230 — intervention group
Group type: EXPERIMENTAL
Intervention: High Meat Group (HM, n = 48) receiving commercial baby jars with a meat content of 12% by weight
Number of subjects: 97
Study 19618230 — intervention group
Group type: COMPARATOR
Intervention: Low Meat Group (LM, n = 49) receiving meals with meat 8% by weight
Number of subjects: 97
Study 18356842 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/day CLA (50:50 cis-9, trans-11:trans-10, cis-12) and 3 g/day n-3 LC-PUFA
Number of subjects: 59
Study 18356842 — intervention group
Group type: COMPARATOR
Intervention: 6 g/day control fat
Number of subjects: 59
Study 15823638 — intervention group
Group type: EXPERIMENTAL
Intervention: PTr (combined strength and endurance exercises) four times per week, twice supervised and twice at home, during 26 weeks.
Number of subjects: 61
Study 12091192 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 156
Study 12091192 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 156
Study 12091192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 12666963 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planning (one session of one hour)
Number of subjects: 14
Study 12666963 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 25% dental gel (ELYZOL DENTAL GEL) applied on day 0 and day 7
Number of subjects: 14
Study 12666963 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling adjunctive to metronidazole 25%
Number of subjects: 14
Study 12666963 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 14
Study 8691500 — intervention group
Group type: EXPERIMENTAL
Intervention: HMO intervention (mailed personal letters and newsletter articles)
Number of subjects: 574
Study 1797462 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing IUD (LNg 20)
Number of subjects: 5
Study 1797462 — intervention group
Group type: COMPARATOR
Intervention: Copper T 380Ag IUD
Number of subjects: 5
Study 1797462 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IUDs
Number of subjects: 5
Study 6689038 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol administration (0.75 micrograms every 6 hr)
Number of subjects: 8
Study 6689038 — intervention group
Group type: COMPARATOR
Intervention: Control (low Ca diet, 4.2 +/- 0.9 mmoles Ca/day)
Number of subjects: 8
Study 6689038 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol administration
Number of subjects: 8
Study 6689038 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study 29869037 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA6/6-matched haplo‐HSCT
Number of subjects: 27
Study 29017069 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive self-control training (CSCT) program for 8 weeks with a 4-month follow-up consolidation program.
Number of subjects: 74
Study 29017069 — intervention group
Group type: COMPARATOR
Intervention: Control group received only pre-post-and-follow-up measurements.
Number of subjects: 74
Study 26658121 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel teat (NT)
Number of subjects: 0
Study 26658121 — intervention group
Group type: COMPARATOR
Intervention: Conventional teat (CT)
Number of subjects: 0
Study 25052080 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires with pictograms
Number of subjects: 76
Study 25052080 — intervention group
Group type: COMPARATOR
Intervention: Questionnaires without pictograms
Number of subjects: 76
Study 22791904 — intervention group
Group type: EXPERIMENTAL
Intervention: Posiphen treatment for 10 days
Number of subjects: 5
Study 22791904 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 5
Study 20555173 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated stretching program (n=22)
Number of subjects: 68
Study 20555173 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard copy version of stretches (n=23)
Number of subjects: 68
Study 20555173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68
Study 17852789 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of clopidogrel until 30 days after OPCAB surgery
Number of subjects: 29
Study 17852789 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clopidogrel)
Number of subjects: 29
Study 15681270 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Manipulative Therapy (MT)
Number of subjects: 240
Study 15681270 — intervention group
Group type: COMPARATOR
Intervention: Combination Therapy (CT)
Number of subjects: 240
Study 15681270 — intervention group
Group type: COMPARATOR
Intervention: Interferential Therapy (IFT)
Number of subjects: 240
Study 11943636 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (15 mg iron/day) for 3 months
Number of subjects: 270
Study 11943636 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (15 mg iron/day) for 6 months
Number of subjects: 270
Study 11943636 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation (15 mg iron/week) for 6 months
Number of subjects: 270
Study 10078179 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-in-the-home (HIH) service
Number of subjects: 100
Study 10078179 — intervention group
Group type: COMPARATOR
Intervention: Hospital
Number of subjects: 100
Study 7742840 — intervention group
Group type: EXPERIMENTAL
Intervention: Aircast SportStirrup
Number of subjects: 25
Study 7742840 — intervention group
Group type: EXPERIMENTAL
Intervention: DonJoy RocketSoc
Number of subjects: 25
Study 7742840 — intervention group
Group type: COMPARATOR
Intervention: Nonbraced control
Number of subjects: 25
Study 8097332 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (GUA) 0.5 mg IV
Number of subjects: 18
Study 8097332 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (GUA) 1.5 mg IV
Number of subjects: 18
Study 8097332 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (CLON) 150 micrograms IV
Number of subjects: 18
Study 3800343 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g mezlocillin every 6 h
Number of subjects: 12
Study 3800343 — intervention group
Group type: COMPARATOR
Intervention: 5 g mezlocillin every 8 h
Number of subjects: 12
Study 30138389 — intervention group
Group type: COMPARATOR
Intervention: Antithrombotic medications (including aspirin-dipyridamole plus clopidogrel, rivaroxaban plus aspirin, warfarin plus aspirin, warfarin plus aspirin and clopidogrel)
Number of subjects: 3131270
Study 30138389 — intervention group
Group type: COMPARATOR
Intervention: Aspirin-dipyridamole plus clopidogrel
Number of subjects: 3131270
Study 30138389 — intervention group
Group type: COMPARATOR
Intervention: Warfarin plus aspirin and clopidogrel
Number of subjects: 3131270
Study 30138389 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban plus aspirin
Number of subjects: 3131270
Study 30138389 — intervention group
Group type: COMPARATOR
Intervention: Warfarin plus aspirin
Number of subjects: 3131270
Study 30138389 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran monotherapy
Number of subjects: 3131270
Study 30138389 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran plus aspirin
Number of subjects: 3131270
Study 30138389 — intervention group
Group type: COMPARATOR
Intervention: Users of antithrombotic medication
Number of subjects: 3131270
Study 30138389 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus clopidogrel
Number of subjects: 3131270
Study 30138389 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 3131270
Study 29897685 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM based acupuncture with manual stimulation
Number of subjects: 70
Study 29897685 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 70
Study 29897685 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 70
Study 25893426 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. low‐dose endotoxin (lipopolysaccharide [LPS])
Number of subjects: 16
Study 25893426 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. fat
Number of subjects: 16
Study 25893426 — intervention group
Group type: COMPARATOR
Intervention: i.v. glycerol (control)
Number of subjects: 16
Study 25893426 — intervention group
Group type: EXPERIMENTAL
Intervention: oral fat
Number of subjects: 16
Study 24823927 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg)
Number of subjects: 20
Study 24823927 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg)
Number of subjects: 20
Study 21709087 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin‐piperaquine with 200 ml milk containing 6.4 g fat (n = 15)
Number of subjects: 30
Study 21709087 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin‐piperaquine with water (fasting patients, n = 15)
Number of subjects: 30
Study 18843535 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive intervention for perinatal depression
Number of subjects: 0
Study 18843535 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive intervention for aggressive disruptive behavior in children
Number of subjects: 0
Study 18843535 — intervention group
Group type: EXPERIMENTAL
Intervention: CACE and IV methods
Number of subjects: 0
Study 16537848 — intervention group
Group type: EXPERIMENTAL
Intervention: AM3
Number of subjects: 70
Study 16537848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 12773121 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowed meal (1708 kJ mixed meal)
Number of subjects: 12
Study 12773121 — intervention group
Group type: COMPARATOR
Intervention: Sham-fed meal (1708 kJ mixed meal)
Number of subjects: 12
Study 11111997 — intervention group
Group type: EXPERIMENTAL
Intervention: Celsior preservation solution (n = 21)
Number of subjects: 41
Study 11111997 — intervention group
Group type: COMPARATOR
Intervention: University of Wisconsin (UW) preservation solution (n = 20)
Number of subjects: 41
Study 11111997 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Celsior and UW preservation solutions
Number of subjects: 41
Study 9639942 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 0
Study 9639942 — intervention group
Group type: COMPARATOR
Intervention: Control (observational studies)
Number of subjects: 0
Study 7825253 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid disease without eye motility complaints (n = 90)
Number of subjects: 203
Study 7825253 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid patients with eye muscle involvement (diplopia, n = 47)
Number of subjects: 203
Study 7825253 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without thyroid disease but with 'big eyes' (n = 51)
Number of subjects: 203
Study 7825253 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 203)
Number of subjects: 203
Study 7825253 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid patients with eye muscle involvement
Number of subjects: 203
Study 7825253 — intervention group
Group type: COMPARATOR
Intervention: Other groups (thyroid disease without eye motility complaints, patients without thyroid disease with 'big eyes')
Number of subjects: 203
Study 3255485 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha-hydroxycholecalciferol (10-20 ng/kg body weight/day)
Number of subjects: 12
Study 3255485 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Control group)
Number of subjects: 12
Study 3255485 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha-hydroxycholecalciferol
Number of subjects: 12
Study 30202030 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg)
Number of subjects: 0
Study 30202030 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib with rifampicin (10 mg/kg)
Number of subjects: 0
Study 30202030 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib with pyrazinamide (25 mg/kg)
Number of subjects: 0
Study 30202030 — intervention group
Group type: COMPARATOR
Intervention: Standard TB drugs alone
Number of subjects: 0
Study 30202030 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib with TB drugs
Number of subjects: 0
Study 26886017 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim administered the same day as chemotherapy
Number of subjects: 192
Study 26886017 — intervention group
Group type: COMPARATOR
Intervention: Pegfilgrastim administered the next day after chemotherapy
Number of subjects: 192
Study 24128381 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking-cessation treatment (SCT) including weekly individual counseling, extended-release bupropion (300 mg/day), nicotine inhaler, and contingency management for smoking abstinence
Number of subjects: 267
Study 24128381 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking (Control)
Number of subjects: 267
Study 22410862 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphatic massage
Number of subjects: 30
Study 22410862 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphatic massage + Compression sleeve
Number of subjects: 30
Study 22410862 — intervention group
Group type: COMPARATOR
Intervention: Control (no compression sleeve)
Number of subjects: 30
Study 20484898 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH PS (n = 24)
Number of subjects: 96
Study 20484898 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH CTA (n = 24)
Number of subjects: 96
Study 20484898 — intervention group
Group type: EXPERIMENTAL
Intervention: No anticoagulation PS (n = 24)
Number of subjects: 96
Study 20484898 — intervention group
Group type: EXPERIMENTAL
Intervention: No anticoagulation CTA (n = 24)
Number of subjects: 96
Study 19292165 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft
Number of subjects: 48
Study 19292165 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft
Number of subjects: 48
Study 19292165 — intervention group
Group type: COMPARATOR
Intervention: Overall
Number of subjects: 48
Study 15782318 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ppm inhaled nitric oxide (iNO)
Number of subjects: 15
Study 15782318 — intervention group
Group type: COMPARATOR
Intervention: Placebo gas (nitrogen)
Number of subjects: 15
Study 12424485 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g dipyrone in 10 ml saline
Number of subjects: 60
Study 12424485 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous injection of 10 ml saline)
Number of subjects: 60
Study 9495568 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol (0.05 g/day) for six months
Number of subjects: 66
Study 9495568 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol (0.05 g/day) + Medroxyprogesterone acetate (MPA; 10 mg/day, per orally for the last ten days)
Number of subjects: 66
Study 9495568 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (600 mg/day, per orally)
Number of subjects: 66
Study 2571307 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Number of subjects: 40
Study 2571307 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 40
Study 2571307 — intervention group
Group type: COMPARATOR
Intervention: Neither glycopyrronium nor vecuronium
Number of subjects: 40
Study 960166 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocarbic general anesthesia (PaCO2 less than 25 torr)
Number of subjects: 100
Study 960166 — intervention group
Group type: COMPARATOR
Intervention: Hypercarbic general anesthesia (PaCO2 greater than 60 torr)
Number of subjects: 100
Study 960166 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative stroke incidence
Number of subjects: 100
Study 30634037 — intervention group
Group type: EXPERIMENTAL
Intervention: MICS CABG
Number of subjects: 88
Study 30634037 — intervention group
Group type: COMPARATOR
Intervention: Sternotomy CABG
Number of subjects: 88
Study 28792334 — intervention group
Group type: EXPERIMENTAL
Intervention: Written, spoken, and visual menus (meal-ordering systems)
Number of subjects: 10